Why is without DAC an important qualifier?

It suggests a distinction from the formulation studied in the cited CJC-1295 human trials. Do not assume a paper's pharmacokinetic or hormone findings apply to a product whose binding modification, sequence or preparation differs. [1]

Does a vendor name establish the chemical identity?

No. A label using modified GRF or CJC terminology should be checked against the actual sequence and formulation. Marketing names are not sufficient evidence that two preparations match or that a particular published trial studied both.

Do changes in GH or IGF-1 prove a clinical benefit?

A measured hormone change is an endpoint, not automatically a demonstrated improvement in health, recovery or longevity. Read what the study measured and avoid replacing that outcome with a broader benefit the trial did not establish. [1]

Can a healthy-volunteer trial establish long-term treatment safety?

It cannot answer every safety question for different patients, formulations or durations. Keep the study population and follow-up in view, and consider FDA's separate safety concerns rather than treating a publication as general reassurance. [1, 2]

Is CJC-1295 without DAC the same as modified GRF 1-29?

Sipra editorial team

Updated 2026-09-16

Do not treat “CJC-1295 without DAC” as an automatically verified synonym for modified GRF 1-29. Online naming can obscure molecular differences. Published long-acting CJC-1295 research does not establish equivalence to a seller’s “without DAC” product. ^{1, 2}

The published CJC-1295 study describes a long-acting growth-hormone-releasing hormone analog. Removing or changing the albumin-binding modification changes what is being discussed.

Seller terminology does not verify what a vial contains. A study of one preparation cannot establish the timing, safety, or effects of a product identified only by a similar name.

Does a rise in growth hormone establish a health benefit?

No. A measured hormone change is a biological finding, not proof of better recovery, longevity, or symptoms. Those outcomes require their own evidence.

What should a trustworthy explanation specify?

It should distinguish the studied molecule from seller terminology and name the route and outcome. It should also acknowledge FDA’s safety concerns and limited clinical data.

Bottom line

Read the identity and study details closely. A “without DAC” label does not make a product interchangeable with trial material.

Explore peptide evidence and safety

Is CJC-1295 without DAC the same as modified GRF 1-29?

Does a rise in growth hormone establish a health benefit?

What should a trustworthy explanation specify?

Frequently asked questions

Related questions

Your Privacy Choices

Your Privacy Choices